Biotech Updates: Acrivon CLIA Lab, Lilly M&A Spree, Defence Radiopharma COO
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
Endometrial Cancer
DiseaseDisease Profile
Endometrial cancer is a malignancy arising from the endometrium, the inner lining of the uterus. It is one of the most common gynecologic cancers in developed countries and is often diagnosed after menopause. Early-stage detection is associated with favorable outcomes.
- Category
- Gynecologic malignancy (uterine cancer)
- Prevalence
- Estimated about 3.8 million women affected worldwide (2015)
- C54.1
Related News
Lilly Amasses $1.5B Stockpile for Oral Obesity Drug as Logistics and Amylin Sectors Surge
Eli Lilly builds $1.5B stockpile for oral obesity drug orforglipron; study shows GLP-1s cut cancer risk; logistics firms invest in cold chain; and amylin drug race heats up with $19B in deals.
Gynaecological Cancers: Late Detection a Persistent Problem, Experts Warn
In Australia, 19 women are diagnosed daily with gynaecological cancer, and experts say late detection is the primary issue. Ovarian cancer is often caught at advanced stages, while endometrial cancer deaths are rising. Personal stories underscore the need for early symptom awareness.
Sensei Biotherapeutics Changes Name to Faeth Therapeutics, Names Former FDA Commissioner to Board
Sensei Biotherapeutics has changed its name to Faeth Therapeutics following its February 2026 acquisition of the biotechnology company. The name change accompanies a $200 million private placement financing to advance PIKTOR, an investigational all-oral multi-node inhibitor targeting the PI3K/AKT/mTOR pathway in endometrial and breast cancer. Topline Phase 2 data in endometrial cancer is anticipated in the second half of 2026.
HRP-Fusion Model Improves HER2-Positive Breast Cancer Response Prediction; HER2-Targeted Therapy Landscape Expands
HRP-Fusion improved pCR prediction in HER2-positive breast cancer at ESMO TAT Asia 2026; experts also reviewed emerging endometrial targets and equitable access to HER2 therapies.
GLP-1 RA drugs show cancer risk reduction but weight regain after cessation
GLP-1 receptor agonists combined with progestin therapy significantly reduce endometrial cancer risk in women with uterine hyperplasia, according to a JAMA Network Open study. A separate meta-analysis finds patients regain 60% of weight lost one year after stopping GLP-1 RAs, with weight regain plateauing at 75.3% of treatment loss.
Tempus AI Launches Preview Tool for Early Cancer Insights Within 24 Hours
Tempus has launched "Preview," an AI-powered tool that provides early cancer insights within one day of sample receipt to inform treatment planning. The tool focuses on high-impact biomarkers including MSI-H, EGFR mutations, and FGFR fusions across several cancer types. The launch aligns with expert emphasis on the critical role of early biomarker testing in personalizing therapy for EGFR-mutated NSCLC.
CAR-NK and CAR-NKT Cell Therapies Show Promise Across Multiple Cancer Types
A phase II trial of TAK-007 CAR-NK therapy in R/R B-cell NHL showed a 60.9% overall response rate. Preclinical CAR-NKT therapy eliminated endometrial tumors in models. Optimized costimulatory domains (2B4-DAP12) boosted CAR-NK tumor killing.
Acrivon Therapeutics launches internal CLIA-certified laboratory in Watertown
Acrivon Therapeutics said its wholly owned laboratory in Watertown received Massachusetts CLIA certification with a full license to conduct patient testing and develop companion diagnostics. The company said the lab is expected to be fully operational in the first half of 2026 and will support targeted therapeutics development.
MSD says sac-TMT met primary endpoints in Phase III endometrial cancer trial
MSD said sacituzumab tirumotecan improved overall survival and progression-free survival in the Phase III TroFuse-005 trial in endometrial cancer. The study also met its objective response rate endpoint.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779109 |
Pelvic Ultra-Hypofractionated Adjuvant Radiotherapy for Endometrial Cancer (PURE-cohort) |
RECRUITING | NA |
| NCT07755436 |
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. |
RECRUITING | PHASE1 |
| NCT07752875 |
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07746024 |
Advancing Risk Stratification in Endometrial Cancer |
ACTIVE_NOT_RECRUITING | |
| NCT07739745 |
Development Of An Endometrial Cancer Educational Tool |
NOT_YET_RECRUITING | NA |
| NCT07737795 |
Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07725159 |
Comparison of Lee-Huang Point and Umbilical Entry for Laparoscopic Success in Endometrial Cancer Patients |
COMPLETED | NA |
| NCT07714070 |
Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia |
NOT_YET_RECRUITING | PHASE2 |
| NCT07702799 |
Low-Residue Diet Versus Rectal Enema Before Laparoscopic Surgery for Endometrial Cancer |
RECRUITING | NA |
| NCT07702721 |
Intraoperative Microscopic Assessment of Lymph Node Status in Gynecological Malignancies |
NOT_YET_RECRUITING |